A Study of PD 0332991 in Patients With Recurrent Rb Positive Glioblastoma
Status:
Terminated
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
This study will determine the efficacy of the small molecule CDK4/6 inhibitor PD 0332991 (as
measured by progression free survival at 6 months) in patients with recurrent glioblastoma
multiforme or gliosarcoma who are Rb positive. A total of 30 patients will be treated; 15
will undergo a planned surgical resection and receive drug for 7 days prior to surgery,
followed by drug after recovery from surgery, and the other 15 patients will receive drug
without a planned surgical procedure.